Table 2.

Change in cardiometabolic disease status from baseline to 5 years postsurgery compared between surgical treatment failure (STF) and non-STF

	Type 2 diabetes (T2D)*		Dyslipidaemia†		Hypertension‡
	STF n=1135	Non-STF n=3878	STF n=1120	Non-STF n=3867	STF n=1126	Non-STF n=3842
No disease at baseline	n=882, %	n=3379, %	n=377, %	n=1616, %	n=735, %	n=2818, %
Disease-free	97.4	98.5	82.0	87.3	83.9§	91.3
Incidence	1.6¶	0.7	9.5§	4.9	9.9§	4.6
Intermittent	1.0	0.9	8.5	7.8	6.1‡	4.0
Disease at baseline	n=253, %	n=499, %	n=743, %	n=2251, %	n=391, %	n=1024, %
Remission	51.4§	66.5	63.7§	81.1	38.6§	54.6
No remission	26.1	22.4	17.2§	8.8	37.6§	27.1
Relapse	22.5§	11.0	19.1§	10.1	23.8**	18.3

*Pharmacologically treated T2D/fasting glucose >7.0 mmol/L/HbA1c>48 mmol/mol.

†Pharmacologically treated dyslipidaemia/LDL >4.1/TG >2.0/HDL <1 mmol/L for males and <1.3 mmol/L for females.

‡Pharmacologically treated blood pressure/systolic ≥140 mm Hg or diastolic blood pressure >90 mm Hg.

§Indicates a statistically significant difference at p<.001.

¶Indicates a statistically significant difference at p<.010.

**Indicates a statistically significant difference at p<.001.

HDL, high-density lipoprotein; LDL, low-density lipoprotein; T2D, type 2 diabetes; TG, triglycerides.